A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastasis
Breast Cancer

Interventions

DRUG: NKTR-102
DRUG: Eribulin
DRUG: Ixabepilone
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Nab-paclitaxel

Sponsor

Nektar Therapeutics